Journal of Autism and Developmental Disorders

, Volume 40, Issue 9, pp 1131–1138 | Cite as

Digestive Enzyme Supplementation for Autism Spectrum Disorders: A Double-Blind Randomized Controlled Trial

  • Sujeeva A. Munasinghe
  • Carolyn Oliff
  • Judith Finn
  • John A. Wray
Original Paper

Abstract

To examine the effects of a digestive enzyme supplement in improving expressive language, behaviour and other symptoms in children with Autism Spectrum Disorder. Randomized, double-blind placebo-controlled trial using crossover design over 6 months for 43 children, aged 3–8 years. Outcome measurement tools included monthly Global Behaviour Rating Scales, Additional Rating Scales of other symptoms by parents and therapists, and monthly completion of the Rescorla Language Development Survey. Compared with placebo, treatment with enzyme was not associated with clinically significant improvement in behaviour, food variety, gastrointestinal symptoms, sleep quality, engagement with therapist, or the Language Development Survey Vocabulary or Sentence Complexity Scores. A small statistically significant improvement on enzyme therapy was seen for the food variety scores. No clinically significant effect improvement of autism symptoms with enzyme use was shown with this trial, however, possible effects on improvement in food variety warrants further detailed investigation.

Keywords

Autism Randomized Double-blind Placebo-controlled Enzymes 

References

  1. Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist: Manual. East Aurora, NY: Slosson Educational Publications.Google Scholar
  2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: Author.Google Scholar
  3. Autism and Developmental Disabilities Monitoring (ADDM) Network. (2007). Prevalence of the autism spectrum disorders in multiple areas of the United States, surveillance years 2000 and 2002. http://www.cdc.gov/ncbddd/dd/addmprevalence.htm. Retrieved 27 July 2007.
  4. Brudnak, M. A., Rimland, B., Kerry, R. E., Dailey, M., Taylor, R., Stayton, B., et al. (2002). Enzyme-based therapy for autism spectrum disorders–Is it worth another look? Medical Hypotheses, 58(5), 422–428.Google Scholar
  5. D’Eufemia et al. (1996). Abnormal intestinal permeability in children with autism. Acta Paediatrica, 85, 1076–1079.Google Scholar
  6. Hanson, E., Kalish, L. A., Bunce, E., Curtis, C., McDaniel, S., Ware, J., et al. (2007). Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. Journal of Autism and Developmental Disorders, 37(4), 628–636.CrossRefPubMedGoogle Scholar
  7. Horvath, K., et al. (1999). Gastrointestinal abnormalities in children with autistic disorder. Journal of Pediatrics, 135, 559–563.CrossRefPubMedGoogle Scholar
  8. Houston, D. (2009). Houston Nutraceuticals Inc. Peptizyde product information accessed 24/12/09 via https://www.houston-enzymes.com/store/product.php?p=6&c=1.
  9. Levy, S. E., Souders, M. C., Wray, J., Jawad, A. F., Gallagher, P. R., Coplan, J., et al. (2003). Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood, 88, 731–736.CrossRefPubMedGoogle Scholar
  10. Matson, J. L., & Fodstadt, J. C. (2009). The treatment of food selectivity and other feeding problems in children with autism spectrum disorders. Research in Autism Spectrum Disorders, 3, 455–461.CrossRefGoogle Scholar
  11. Millward, C., Ferriter, M., Calver, S., & Connell-Jones, G. (2008). Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database of Systematic Reviews, (2). Art. No.: CD003498. doi:10.1002/14651858.CD003498.pub3.
  12. Reichelt, K., & Knivsberg, A. M. (2003). Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutritional Neuroscience, 6(1), 19–28.CrossRefPubMedGoogle Scholar
  13. Rescorla, L. (1989). The language development survey: A screening tool for delayed language in toddlers. Journal of Speech and Hearing Disorders, 54, 587–599.PubMedGoogle Scholar
  14. Sparrow, S. S., Balla, D. A., & Cicchetti, D. (1984). Vineland adaptive behavior scales. Minnesota: AGS Publishing.Google Scholar
  15. Wakefield, A. J., Puleston, J. M., Montgomery, S. M., Anthony, A., O’Leary, J. J., & Murch, S. H. (2002). Review article: The concept of enter-colonic encephalopathy, autism and opioid receptor ligands. Alimentary Pharmacology & Therapeutics, 16, 663–674.CrossRefGoogle Scholar
  16. Weber, W. (2007). Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatric Clinics of North America, 54, 983–1006.Google Scholar
  17. Wetherby, A., & Prizant, B. M. (1993). Communication and symbolic behavior scales. New York: Applied Symbolix.Google Scholar
  18. White, J. F. (2003). Intestinal pathophysiology in autism. Experimental Biology and Medicine, 228, 639–649.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sujeeva A. Munasinghe
    • 1
  • Carolyn Oliff
    • 1
  • Judith Finn
    • 2
  • John A. Wray
    • 1
  1. 1.State Child Development CentreWest PerthAustralia
  2. 2.University of Western AustraliaCrawleyAustralia

Personalised recommendations